The goal of this phase I pilot clinical trial is to evaluate the acceptability, tolerability and effect on blood pressure and biomarkers of Hibiscus sabdariffa drink in pregnant women in the second trimester of pregnancy. The main questions it aims to answer are: Is the drink acceptable to take as a daily dose for a long time? Does drinking the beverage cause negative effects? What is the effect of drink consumption on blood pressure and biomarkers in pregnant women? Each participant was their own control with the values measured before consumption of the beverage and after four weeks of consumption. The participants: * Took a daily dose of the beverage for 4 weeks * Once a week for the four weeks, they answered the acceptability and tolerability questionnaires * Before starting to consume the beverage and after the 4 weeks of consumption, they had their blood pressure measured, and samples taken for biomarker measurements.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
10
A daily dose of Hibiscus sabdariffa drink that provides 9.6 mg of anthocyanins
MEDOMAI
Cuernavaca, Morelos, Mexico
Acceptability of Hibiscus sabdariffa drink
Beverage acceptability was measured using a sensory evaluation with 7-point hedonic scale of the attributes of odor, color, flavor, mouthfeel, aftertaste, and overall appearance through questionnaires applied once a week for 4 weeks. The outcome measures are based on a 7-point hedonic scale where every participant can answer in every attribute evaluated: 1. I dislike it a lot 2. I dislike it moderately 3. I dislike it a little 4. I neither like it nor dislike it 5. I like it a little 6. I like it moderately 7. I like it a lot
Time frame: 4 weeks
Tolerability of Hibiscus sabdariffa Drink
Tolerability was measured by the presence or absence of gastrointestinal symptoms such as nausea, regurgitation, vomiting, constipation, diarrhea, flatulence, and abdominal pain through questionnaires applied once a week for 4 weeks. The outcome measures for the tolerability assessment were the presence or absence of gastrointestinal symptoms mentioned in the previous paragraph, where participants had the option to respond: 1. Symptom absent 2. Symptom present but not bothersome 3. Symptom present and somewhat bothersome, but does not interfere with daily activities or sleep 4. Symptom present and bothersome because it interferes with daily activities or sleep 5. Required medical attention
Time frame: 4 weeks
Blood pressure
Blood pressure was measured using the Korotkoff auscultation method, These measurements were taken before starting to consume the beverage and at the end of the 4-week trial. The outcome measures were the average of the measurements of the 10 participants expressed as mm/Hg of systolic and diastolic pressure.
Time frame: 4 weeks
Biomarkers glucose
Glucose was measured by taking a blood sample, These measurements were taken before starting to consume the beverage and at the end of the 4-week trial. The outcome measures were the average of the measurements of the 10 participants expressed as mg/dL.
Time frame: 4 weeks
Biomarkers cholesterol
Cholesterol was measured by taking a blood sample, These measurements were taken before starting to consume the beverage and at the end of the 4-week trial. The outcome measures were the average of the measurements of the 10 participants expressed as mg/dL.
Time frame: 4 weeks
Biomarkers triglycerides
Triglycerides were measured by taking a blood sample, These measurements were taken before starting to consume the beverage and at the end of the 4-week trial. The outcome measures were the average of the measurements of the 10 participants expressed as mg/dL.
Time frame: 4 weeks
Biomarkers creatinine
Creatinine was measured by taking a blood sample, These measurements were taken before starting to consume the beverage and at the end of the 4-week trial. The outcome measures were the average of the measurements of the 10 participants expressed as mg/dL.
Time frame: 4 weeks
Biomarkers proteinuria
Participants were also asked to provide a urine sample to determine proteinuria. These measurements were taken before starting to consume the beverage and at the end of the 4-week trial. The results were presented as the number of positive cases for proteinuria, as well as the average of positive cases expressed as mg/dL.
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.